Tumor Suppressor Gene Aberrations in Acute Myelogenous Leukemia

References

• Finch, C.E. and Schneider, E. L. (1996). Aging and geriatrie medicine: biology of aging. In Cecil Textbook of Medicine, edited by J. C. Bennett and F. Plum, pp. 12–15, Philadelphia. W. B. Saunders Co.
   Google Scholar
• Scheinberg, D. A., Maslak, P. and Weiss, M. (1997). Acute Leukemias. In Cancer: Principles & Practice of Oncology, edited by T. Vincent, J. DeVita, S. Hellman and S. Rosenberg, pp. 2293–2321, Cancer: Principles & Practice of Oncology. Philadelphia. Lippincott-Raven.
   Google Scholar
• Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. o., Mcintyre, O. R. and Frei, E. 3rd. (1994). Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B, N Engl J Med, 331, 896–903.
   PubMed Web of Science ®Google Scholar
• Jehn, U. (1994). Phase II-trial of double-consolidation following intensive induction treatment for improvement of survival in elderly patients with acute myeloid leukemia, Leuk Lymphoma, 12, 435–40.
   PubMed Web of Science ®Google Scholar
• Heyll, A., Aul, C., Gogolin, F., Runde, V., Sohngen, D., Meckenstock, G., Wolf, H. H., Zahner, J., Burk, M., Winkelmann, M. and Schneider, W. (1994). Results of conventional-dose cytosine arabinoside and idarubicin in elderly patients with acute myeloid leukemia, Ann Henmtol, 68, 279–83.
   PubMed Web of Science ®Google Scholar
• Ryan, D. H., Kopecky, K. J., Head, D., Grever, M. R., Shiaer, S. M., Lipschitz, D. A., Hynes, H. E., Vial, R. H., Veith, R. W. and Gumbart, C. H. (1992). Analysis of treatment failure in acute nonlymphocytic leukemia patients over fifty years of age. A Southwest Oncology Group study, Am J Clin Oncol, 15, 69–75.
   PubMed Web of Science ®Google Scholar
• Rowley, J. D. (1990). Recurring chromosome abnormalities in leukemia and lymphoma, Semin Hematol, 27, 122–36.
   PubMed Web of Science ®Google Scholar
• Smith, M. A., McCaffrey, R. P. and Karp, J. E. (1996). The secondary leukemias: challenges and research directions, J Natl Cancer Inst, 88, 407–418.
   PubMed Web of Science ®Google Scholar
• Radich, J. P., Kopecky, K. J., Appelbaum, F., Willman, C. L. and Collins, S. J. (1992). N-ras mutations in acute myelogenous leukemia: a review of the current literature and an update of the Southwest Oncology Group experience, Leak Lymphoma, 6, 325–334.
   Web of Science ®Google Scholar
• Neubauer, A., Dodge, R. K., George, S. L., Davey, F. R., Silver, R. T., Schiffer, C. A., Mayer, R. J., Ball, E. D., Wurster-Hill, D., Bloomfield, C. D. and Liu, E. T. (1994). Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia, Blood, 83, 1603–11.
   PubMed Web of Science ®Google Scholar
• Coghlan, D. W., Morley, A. A., Matthews, J. P. and Bishop, J. F. (1994). The incidence and prognostic signficance of mutations in codon 13 on the N-ras gene in Acute Myeloid Leukemia, Leukemia, 8, 1682–1687.
   PubMed Web of Science ®Google Scholar
• Fourth International Workshop on Chromosomes in Leukemia. (1984). Cancer Genet Cytogenet, 11, 249–360.
   PubMed Web of Science ®Google Scholar
• Kiyoi, H., Naoe, T., Nakano, Y., Yokota, S., Minami, S., Miyawaki, S., Asou, N., Kuriyama, K., Jinnai, I., Shimazaki, C., Akiyama, H., Saito, K., Oh, H., Motoji, T., Omoto, E., Saito, H., Ohno, R. and Ueda, R. (1999). Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia, Blood, 93, 3074–80.
   PubMed Web of Science ®Google Scholar
• Brashem-Stein, C., Flowers, D. A. and Bernstein, I. D. (1996). Regulation of colony forming cell generation by flt-3 ligand, Br J Haematol, 94, 17–22.
   PubMed Web of Science ®Google Scholar
• Chang, F., Syrjänen, S. and Syränen, K. (1995). Implications of the p53 tumorsuppressor gene in clinical oncology, J Clin Oncol, 13, 1009–1022.
   PubMed Web of Science ®Google Scholar
• Shieh, S.-Y., Ikeda, M., Taya, Y. and Prives, C. (1997). DNA damage-induced phosphorylation pf p53 alleviates inhibition by MDM2, Cell, 91, 325–334.
   PubMed Web of Science ®Google Scholar
• Levine, A. J. (1997). p53, the cellular gatekeeper for growth and division, Cell, 88, 323–331.
   PubMed Web of Science ®Google Scholar
• Banker, D. E., Groudine, M., Norwood, T. and Appelbaum, F. R. (1997). Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia, Blood, 89, 243–55.
   PubMed Web of Science ®Google Scholar
• Felix, C. A., Hosier, M. R., Provisor, D., Salhany, K., Sexsmith, E. A., Slater, D. J., Cheung, N. K., Winick, N. J., Strauss, E. A., Heyn, R., Lange, B. J. and Malkin, D. (1996). The p53 gene in pediatric therapyrelated leukemia and myelodysplasia, Blood, 87, 4376–81.
   PubMed Web of Science ®Google Scholar
• Ludwig, L., Schulz, A. S., Janssen, J. W. G., Grünewald, K. and Bartram, C. R. (1992). P53 mutations in Myelodysplastic Syndromes, Leukemia, 6, 1302–1304.
   PubMed Web of Science ®Google Scholar
• Abo, J., Inokuchi, K., Dan, K. and Nomura, T. (1993). p53 and N-ras mutations in two new leukemia cell lines established from a patient with multilineage CD7-positive acute leukemia, Blood, 82, 2829–2836.
   PubMed Web of Science ®Google Scholar
• Sugimoto, K., Hirano, N., Toyoshima, H., Chiba, S., Mano, H., Takaku, F., Yazaki, Y. and Hirai, H. (1993). Mutations of the p53 gene in Myelodysplastic Syndrome (MDS) and MDS-derived leukemia, Blood, 81, 3022–3026.
   PubMed Web of Science ®Google Scholar
• Fenaux, P., Jonveaux, P., Quiquandon, I., Laï, J. L., Pignon, J. M., Loucheux-Lefebvre, M. H., Bauters, F., Berger, R. and Kerckaert, J. P. (1991). P53 gene mutations in acute myeloid leukemia with 17p monosomy, Blood, 78, 1652–1657.
   PubMed Web of Science ®Google Scholar
• Zhang, W., Hu, G., Estey, E., Hester, J. and Deisseroth, A. (1992). Altered conformation of the p53 protein in myeloid leukemia cells and mitogen-stimulated normal blood cells, Oncogene, 7, 1645–1647.
   PubMed Web of Science ®Google Scholar
• Parry, T. E. (1997). The non-random distribution of point mutations in leukaemia and myelodysplasia—a possible pointer to their aetiology, Leukemia Res, 21, 559–74.
   PubMed Web of Science ®Google Scholar
• Sakai, E. and Tsuchida, N. (1992). Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes, Oncogene, 7, 927–33.
   PubMed Web of Science ®Google Scholar
• Nylander, K., Nilsson, P., Mehle, C. and Roos, G. (1995). p53 mutations, protein expression and cell proliferation in squamous cell carcinomas of the head and neck, Br J Cancer, 71, 826–830.
   PubMed Web of Science ®Google Scholar
• D'Amico, D., Carbone, D., Mitsudomi, T., Nau, M., Fedorko, J., Russell, E., Johnson, B., Buchhagen, D., Bodner, S., Phelps, R., Gazdar, A. and Minna, J. (1992). High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors, Oncogene, 7, 339–46.
   PubMed Web of Science ®Google Scholar
• Fagin, J. A., Matsuo, K., Karmakar, A., Chen, D. L., Tang, S.-H. and Koeffler, H. P. (1993). High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas, J Clin Invest, 91, 179–184.
   PubMed Web of Science ®Google Scholar
• Lassus, P., Ferlin, M., Piette, J. and Hibner, U. (1996). Anti-apoptotic activity of low levels of wild-type p53, EMBO J, 15, 4566–73.
   PubMed Web of Science ®Google Scholar
• Venkatachalam, S., Shi, Y. P., Jones, S. N., Vogel, H., Bradley, A., Pinkel, D. and Donehower, L. A. (1998). Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation, EMBO J, 17, 4657–67.
   PubMed Web of Science ®Google Scholar
• Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P. and Fenaux, P. (1994). p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies, Blood, 84, 3148–57.
   PubMed Web of Science ®Google Scholar
• Head, D. R. (1996). Revised classification of acute myeloid leukemia, Leukemia, 10, 1826–31.
   PubMed Web of Science ®Google Scholar
• Kaneko, H., Misawa, S., Horiike, S., Nakai, H. and Kashima, K. (1995). TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities, Blood, 85, 2189–93.
   PubMed Web of Science ®Google Scholar
• Kelman, Z., Prokocimer, M., Pellar, S., Kahn, Y., Rechavi, G., Manor, Y., Cohen, A. and Rotter, V. (1989). Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia, Blood, 74, 2318–2324.
   PubMed Web of Science ®Google Scholar
• Ahuja, H., Bar-Eli, M., Advani, S. H., Benchimol, S. and Cline, M. J. (1989). Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia, Proc. Natl. Acad. Sci. USA, 86, 6783–6787.
   PubMed Web of Science ®Google Scholar
• Sameshima, Y., Akiyama, T., Mori, N., Mizoguchi, H., Toyoshima, K., Sugimura, T., Terada, M. and Yokota, J. (1990). Point mutation of the p53 gene resulting in splicing inhibition in small cell lung carcinoma, Biochem Biophys Res Commun, 173, 697–703.
   PubMed Web of Science ®Google Scholar
• Lai, M. Y., Chang, H. C., Li, H. P., Ku, C. K., Chen, P.J., Sheu, J. C., Huang, G. T., Lee, P. H. and Chen, D. S. (1993). Splicing mutations of the p53 gene in human hepatocellular carcinoma, Cancer Res, 53, 1653–6.
   PubMed Web of Science ®Google Scholar
• Jolly, K. W., Malkin, D., Douglass, E. C., Brown, T. F., Sinclair, A. E. and Look, A. T. (1994). Splice-site mutation of the p53 gene in a family with hereditary breast-ovarian cancer, Oncogene, 9, 97–102.
   PubMed Web of Science ®Google Scholar
• Kressner, U., Inganas, M., Byding, S., Blikstad, I., Pahlman, L., Glimelius, B. and Lindmark, G. (1999). Prognostic value of p53 genetic changes in colorectal cancer, J Clin Oncol, 17, 593–9.
   PubMed Web of Science ®Google Scholar
• Zhang, W. and Deisseroth, A. B. (1994). Conformational change of p53 protein in growth factor-stimulated human myelogenous leukemia cells, Leuk Lymphoma, 14, 251–255.
   PubMed Web of Science ®Google Scholar
• Schneider-Stock, R., Oda, Y. and Roessner, A. (1997). New splicing mutation in exon 5–6 of the p53-tumor suppressor gene in a malignant schwannoma, Hum Mutat, 9, 91–4.
   PubMed Web of Science ®Google Scholar
• Wolf, D. and Rotter, V. (1984). Inactivation of p53 gene expression by an insertion of Moloney murine leukemia virus-like DNA sequence, Mol Cell Biol, 4, 1402–1410.
   PubMed Web of Science ®Google Scholar
• Mowat, M., Cheng, A., Kimura, N., Bernstein, A. and Benchimo, S. (1985). Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by Friend virus, Nature, 314, 633–636.
   PubMed Web of Science ®Google Scholar
• Szekely, L., Selivanova, G., Magnusson, K. P., Klein, G. and Wiman, K. G. (1993). EBNA-5, and Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53, Proc Natl Acad Sci USA, 90, 5455–5459.
   PubMed Web of Science ®Google Scholar
• Sarnow, P., Ho, Y. S., Williams, J. and Levine, A. J. (1982). Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically asociated with the same 54 kd cellular protein in transformed cells, Cell, 28, 387–394.
   PubMed Web of Science ®Google Scholar
• Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L. and Vogelstein, B. (1992). Amplification of a gene encoding a p53-associated protein in human sarcomas, Nature, 358, 80–83.
   PubMed Web of Science ®Google Scholar
• Leach, F. S., Tokino, T., Meltzer, P., Burrell, M., Oliner, J. D., Smith, S., Hill, D. E., Sidransky, D., Kinzler, K. W. and Vogelstein, B. (1993). p53 mutation and MDM2 amplification in human soft tissue sarcomas, Cancer Res, 53, 2231–2234.
   PubMed Web of Science ®Google Scholar
• Sheikh, M. S., Shao, Z.-M., Hussain, A. and Fontana, J. (1993). The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma, Cancer Res, 53, 3226–3228.
   PubMed Web of Science ®Google Scholar
• Bueso-Ramos, C. E., Yang, Y., deLeon, E., McCown, P., Stass, S. A. and Albitar, M. (1993). The human MDM-2 oncogene is overexpressed in leukemias, Blood, 82, 2617–2623.
   PubMed Web of Science ®Google Scholar
• Momand, J., Zambetti, G. P., Olson, D. C., George, D. and Levine, A. J. (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transformation, Cell, 69, 1237–1245.
   PubMed Web of Science ®Google Scholar
• Kaghad, M., Bonnet, H., Yang, A., Creancler, L., Biscan, J.-C., Valent, A., Minty, A., Chalon, P., Lelias, J.- M., Durmont, X., Ferrara, P., McKeon, F. and Caput, D. (1997). Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other cancers, Cell, 90, 809–819.
   PubMed Web of Science ®Google Scholar
• Brodeur, G. M., Sekhon, G. and Goldstein, M. N. (1977). Chromosomal aberrations in human neuroblastomas, Cancer, 40, 2256–63.
   PubMed Web of Science ®Google Scholar
• Dracopoli, N. C., Harnett, P., Bale, S. J., Stanger, B. Z., Tucker, M. A., Housman, D. E. and Kefford, R. F. (1989). Loss of alleles from the distal short arm of chromosome 1 occurs late in melanoma tumor progression, Proc Natl Acad Sci USA, 86, 4614–8.
   PubMed Web of Science ®Google Scholar
• Sozzi, G., Bertoglio, M. G., Pilotti, S., Rilke, F., Pierotti, M. A. and Della Porta, G. (1988). Cytogenetic studies in primary and metastatic neuroendocrine Merkel cell carcinoma, Cancer Genet Cytogenet, 30, 151–8.
   PubMedGoogle Scholar
• Genuardi, M., Tsihira, H., Anderson, D. E. and Saunders, G. F. (1989). Distal deletion of chromosome Ip in ductal carcinoma of the breast, Am J Hum Genet, 45, 73–82.
   PubMed Web of Science ®Google Scholar
• Clurman, B. and Groudine, M. (1997). Killer in search of a motive?, Nature, 389, 122–123.
   PubMed Web of Science ®Google Scholar
• Jost, C. A., Marin, M. C. and Kaelin, W. G. Jr., (1997). p73 is a human p53-related protein that can induce apoptosis, Nature, 389, 191–4.
   PubMed Web of Science ®Google Scholar
• Mai, M., Yokomizo, A., Qian, C., Yang, P., Tindall, D. J., Smith, D. I. and Liu, W. (1998). Activation of p73 silent allele in lung cancer, Cancer Res, 58, 2347–9.
   PubMed Web of Science ®Google Scholar
• Nomoto, S., Haruki, N., Kondo, M., Konishi, H. and Takahashi, T. (1998). Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers, Cancer Res, 58, 1380–3.
   PubMed Web of Science ®Google Scholar
• Mai, M., Huang, H., Reed, C., Qian, C., Smith, J. S., Alderete, B., Jenkins, R., Smith, D. I. and Liu, W. (1998). Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions, Genomics, 51, 359–63.
   PubMed Web of Science ®Google Scholar
• Sunahara, M., Ichimiya, S., Nimura, Y., Takada, N., Sakiyama, S., Sato, Y., Todo, S., Adachi, W., Amano, J. and Nakagawara, A. (1998). Mutational analysis of the p73 gene localized at chromosome 1p36.3 in colorectal carcinomas, Int J Oncol, 13, 319–23.
   PubMed Web of Science ®Google Scholar
• Takahashi, H., Ichimiya, S., Nimura, Y., Watanabe, M., Furusato, M., Wakui, S., Yatani, R., Aizawa, S. and Nakagawara, A. (1998). Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma, Cancer Res, 58, 2076–7.
   PubMed Web of Science ®Google Scholar
• Fero, M. L., Randel, E., Gurley, K. E., Roberts, J. M. and Kemp, C. J. (1998). The murine gene p27Kip1 is haploinsufficient for tumor suppression, Nature, 396, 177–180.
   PubMed Web of Science ®Google Scholar
• Lee, W. H., Bookstein, R., Hong, F., Young, L. J., Shew, J. Y. and Lee, E. Y. (1987). Human retinoblastoma susceptibility gene: cloning, identification, and sequence, Science, 235, 1394–9.
   PubMed Web of Science ®Google Scholar
• Ludlow, J. W., Shon, J., Pipas, J. M., Livingston, D. M. and DeCaprio, J. A. (1990). The retinoblastoma susceptibility gene product undergoes cell cycle-dependent dephosphorylation and binding to and release from SV40 large T, Cell, 60, 387–96.
   PubMed Web of Science ®Google Scholar
• Shew, J. Y., Ling, N., Yang, X. M., Fodstad, O. and Lee, W. H. (1989). Antibodies detecting abnormalities of the retinoblastoma susceptibility gene product (pp110RB) in osteosarcomas and synovial sarcomas, Oncogene Res, 4, 205–14.
   PubMedGoogle Scholar
• Toguchida, J., Ishizaki, K., Sasaki, M. S., Nakamura, Y., Ikenaga, M., Kato, M., Sugimot, M., Kotoura, Y. and Yamamuro, T. (1989). Preferential mutation of paternally derived RB gene as the initial event in sporadic osteosarcoma, Nature, 338, 156–8.
   PubMed Web of Science ®Google Scholar
• Huang, H. J., Yee, J. K., Shew, J. Y., Chen, P. L., Bookstein, R., Friedmann, T., Lee, E. Y. and Lee, W. H. (1988). Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells, Science, 242, 1563–6.
   PubMed Web of Science ®Google Scholar
• Lee, E. Y., Bookstein, R., Young, L. J., Lin, C. J., Rosenfeld, M. G. and Lee, W. H. (1988). Molecular mechanism of retinoblastoma gene inactivation in retinoblastoma cell line Y79, Proc Natl Acad Sci USA, 85, 6017–21.
   PubMed Web of Science ®Google Scholar
• Lee, E. Y., To, H., Shew, J. Y., Bookstein, R., Scully, P. and Lee, W. H. (1988). Inactivation of the retinoblastoma susceptibility gene in human breast cancers, Science, 241, 218–21.
   PubMed Web of Science ®Google Scholar
• Harbour, J. W., Lai, S. L., Whang-Peng, J., Gazdar, A. F., Minna, J. D. and Kaye, F. J. (1988). Abnormalities in structure and expression of the human retinoblastoma gene in SCLC, Science, 241, 353–7.
   PubMed Web of Science ®Google Scholar
• Goddard, A. D., Balakier, H., Canton, M., Dunn, J., Squire, J., Reyes, E., Becker, A., Phillips, R. A. and Gallie, B. L. (1988). Infrequent genomic rearrangement and normal expression of the putative RB1 gene in retinoblastoma tumors, Mol Cell Biol, 8, 2082–8.
   PubMed Web of Science ®Google Scholar
• Toguchida, J., Ishizaki, K., Sasaki, M. S., Ikenaga, M., Sugimoto, M., Kotoura, Y. and Yamamuro, T. (1988). Chromosomal reorganization for the expression of recessive mutation of retinoblastoma susceptibility gene in the development of osteosarcoma, Cancer Res, 48, 3939–43.
   PubMed Web of Science ®Google Scholar
• Mendoza, A. E., Shew, J. Y., Lee, E. Y., Bookstein, R. and Lee, W. H. (1988). A case of synovial sarcoma with abnormal expression of the human retinoblastoma susceptibility gene, Hum Pathol, 19, 487–9.
   PubMed Web of Science ®Google Scholar
• Ahuja, H. G., Jat, P. S., Foti, A., Bar-Eli, M. and Cline, M. J. (1991). Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia, Blood, 78, 3259–68.
   PubMed Web of Science ®Google Scholar
• Jamal, R., Gale, R. E., Shaun, N., Thomas, B., Wheatley, K. and Linch, D. C. (1996). The retinoblastoma gene (rb1) in acute myeloid leukaemia: analysis of gene rearrangements, protein expression and comparison of disease outcome, Br J Haematol, 94, 342–51.
   PubMed Web of Science ®Google Scholar
• Barbosa de Melo, M., Costa, F. F., Saad, S. T., Lorand-Metze, I., Bordin, S. and Ahmad, N. N. (1998). Molecular analysis of the retinoblastoma (RB1) gene in acute myeloid leukemia patients, Leukemia Res, 22, 787–92.
   PubMed Web of Science ®Google Scholar
• Wallace, M. R., Marchuk, D. A., Andersen, L. B., Letcher, R., Odeh, H. M., Saulino, A. M., Fountain, J. W., Brereton, A., Nicholson, J., Mitchell, A. L., et al. (1990). type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients, Science, 249, 181–6.
   PubMed Web of Science ®Google Scholar
• Li, Y., O'Connell, P., Breidenbach, H. H., Cawthon, R., Stevens, J., Xu, G., Neil, S., Robertson, M., White, R. and Viskochil, D. (1995). Genomic organization of the neurofibromatosis 1 gene (NF1), Genomics, 25, 9–18.
   PubMed Web of Science ®Google Scholar
• Matsui, I., Tanimura, M., Kobayashi, N., Sawada, T., Nagahara, N. and Akatsuka, J. (1993). Neurofibromatosis type 1 and childhood cancer, Cancer, 72, 2746–54.
   PubMed Web of Science ®Google Scholar
• Xu, G. F., Lin, B., Tanaka, K., Dunn, D., Wood, D., Gesteland, R., White, R., Weiss, R. and Tamanoi, F. (1990). The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae, Cell, 63, 835–41.
   PubMed Web of Science ®Google Scholar
• Hettich, L. and Marshall, M. (1994). Structural Analusis of the Ras GTPase Activating Protein catalytic domain by semirandom mutagenesis: implications for a mechanism of interaction with Ras-GTP, Cancer Res, 54, 5438–5444.
   PubMed Web of Science ®Google Scholar
• Martin, G. A., Viskochil, D., Bollag, G., McCabe, P. C., Crosier, W. J., Haubruck, H., Conroy, L., Clark, R., O'Connell, P., Cawthon, R. M., Innis, M. A. and McCormick, F. (1990). The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21, Cell, 63, 843–9.
   PubMed Web of Science ®Google Scholar
• Largaespada, D. A., Brannan, C. I., Jenkins, N. A. and Copeland, N. G. (1996). Nf1 deficiency causes Rasmediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia, Nat Genet, 12, 137–43.
   PubMed Web of Science ®Google Scholar
• Side, L., Taylor, B., Cayouette, M., Conner, E., Thompson, P., Luce, M. and Shannon, K. (1997). Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders, N Engl J Med, 336, 1713–20.
   PubMed Web of Science ®Google Scholar
• Niemeyer, C. M., Arico, M., Basso, G., Biondi, A., Cantu Rajnoldi, A., Creutzig, U., Haas, O., Harbott, J., Hasle, H., Kerndrup, G., Locatelli, F., Mann, G., Stollmann-Gibbels, B., van't Veer-Korthof, E. T., van Wering, E. and Zimmermann, M. (1997). Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS), Blood, 89, 3534–43.
   PubMed Web of Science ®Google Scholar
• Li, Y., Bollag, G., Clark, R., Stevens, J., Conroy, L., Fults, D., Ward, K., Friedman, E., Samowitz, W., Robertson, M., Bradley, P., McCormick, F., White, R. and Cawthon, R. (1992). Somatic mutations in the neurofibromatosis 1 gene in human tumors, Cell, 69, 275–81.
   PubMed Web of Science ®Google Scholar
• Luria, D., Avigad, S., Cohen, I. J., Stark, B., Weitz, R. and Zaizov, R. (1997). p53 mutation as the second event in juvenile chronic myelogenous leukemia in a patient with neurofibromatosis type 1, Cancer, 80, 2013–8.
   PubMed Web of Science ®Google Scholar
• Lee, Y. Y., Kim, W. S., Bang, Y. J., Jung, C. W., Park, S., Yoon, W. J., Cho, K. S., Kim, I. S., Jung, T. J., Choi, I. Y., Kim, B. K., Kim, N. K. and Koeffler, H. P. (1995). Analysis of mutations of neurofibromatosis type 1 gene and N-ras gene in acute myelogenous leukemia, Stem Cells, 13, 556–63.
   PubMed Web of Science ®Google Scholar
• Preudhomme, C., Vachee, A., Quesnel, B., Wattel, E., Cosson, A. and Fenaux, P. (1993). Rare occurrence of mutations of the FLR exon of the neurofibromatosis 1 (NF1) gene in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), Leukemia, 7, 1071.
   PubMed Web of Science ®Google Scholar
• Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G. and Sherr, C. J. (1997). Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF, Cell, 91, 649–59.
   PubMed Web of Science ®Google Scholar
• Hall, M. and Peters, G. (1996). Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer, Advances in Cancer Research, 68, 67–108.
   PubMed Web of Science ®Google Scholar
• Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., 3rd, Johnson, B. E. and Skolnick, M. H. (1994). A cell cycle regulator potentially involved in genesis of many tumor types, Science, 264, 436–40.
   PubMed Web of Science ®Google Scholar
• Serrano, M., Hannon, G. J. and Beach, D. (1993). A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4, Nature, 366, 704–707.
   PubMed Web of Science ®Google Scholar
• Quelle, D. E., Zindy, F., Ashmun, R. A. and Sherr, C. J. (1995). Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest, Cell, 83, 993–1000.
   PubMed Web of Science ®Google Scholar
• Mao, L., Merlo, A., Bedi, G., Shapiro, G. I., Edwards, C. D., Rollins, B. J. and Sidransky, D. (1995). A novel p16INK4A transcript, Cancer Res, 55, 2995–7.
   PubMed Web of Science ®Google Scholar
• Stone, S., Jiang, P., Dayananth, P., Tavtigian, S. V., Katcher, H., Parry, D., Peters, G. and Kamb, A. (1995). Complex structure and regulation of the P16 (MTS1) locus, Cancer Res, 55, 2988–94.
   PubMed Web of Science ®Google Scholar
• Hannon, G. J. and Beach, D. (1994). p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest, Nature, 371, 257–61.
   PubMed Web of Science ®Google Scholar
• Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F. and Sherr, C. J. (1998). Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2, Pro Natl Acad Sci USA, 95, 8292–7.
   PubMed Web of Science ®Google Scholar
• Della Valle, V., Duro, D., Bernard, O. and Larsen, C. J. (1997). The human protein p19ARF is not detected in hemopoietic human cell lines that abundantly express the alternative beta transcript of the p16INK4a/MTS1 gene, Oncogene, 15, 2475–81.
   PubMed Web of Science ®Google Scholar
• Bates, S., Phillips, A. C., Clark, P. A., Scott, F., Peters, G., Ludwig, R. L. and Vousden, K. H. (1998). p14ARF links the tumour suppressor RB and p53, Nature, 395, 124–125.
   PubMed Web of Science ®Google Scholar
• Palmero, I., Pantoja, C. and Serrano, M. (1998). p19ARF links the tumour suppressor p53 to RAS, Nature, 395, 125–126.
   PubMed Web of Science ®Google Scholar
• Radfar, A., Unnikrishnan, I., Lee, H. W., DePinho, R. A. and Rosenberg, N. (1998). p19(Arf) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation, Proc. Natl. Acad. Sci. USA, 95, 13194–9.
   PubMed Web of Science ®Google Scholar
• Herman, J. G., Jen, J., Merlo, A. and Baylin, S. B. (1996). Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B, Cancer Res, 56, 722–7.
   PubMed Web of Science ®Google Scholar
• Nakamaki, T., Kawamata, N., Schwaller, J., Tobler, A., Fey, M., Pakkala, S., Lee, Y. Y., Kim, B. K., Fukuchi, K., Tsuruoka, N., Kahan, J., Miller, C. W. and Koeffler, H. P. (1995). Structural integrity of the cyclin-dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias, Br J Haematol, 91, 139–49.
   PubMed Web of Science ®Google Scholar
• Sill, H., Goldman, J. M. and Cross, N. C. (1995). Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia, Blood, 85, 2013–6.
   PubMed Web of Science ®Google Scholar
• Drexler, H. G. (1998). Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells, Leukemia, 12, 845–59.
   PubMed Web of Science ®Google Scholar
• Zion, M., Ben-Yehuda, D., Avraham, A., Cohen, O., Wetzler, M., Melloul, D. and Ben-Neriah, Y. (1994). Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia, Proc Natl Acad Sci USA, 91, 10722–10726.
   PubMed Web of Science ®Google Scholar
• Litz, C. E., Vos, J. A. and Copenhaver, C. M. (1996). Aberrant methylation of the major breakpoint cluster region in chronic myeloid leukemia, Blood, 88, 2241–2249.
   PubMed Web of Science ®Google Scholar
• Felgner, J., Kreipe, H., Heidorn, K., Jaquet, K., Zschunke, F., Radzun, H. J. and Parwaresch, M. R. (1991). Increased methylation of the c-fms protooncogene in acute myelomonocytic leukemias, Pathobiology, 59, 293–8.
   PubMed Web of Science ®Google Scholar
• Wu, H.-K., Weksberg, R., Minden, M. D. and Squire, J. A. (1997). Loss of imprinting of human insulin-like growth factor II gene, IGF2, in acute myeloid leukemia, Biochem Biophys Res Commun, 231, 466–472.
   PubMed Web of Science ®Google Scholar
• Ogawa, S., Hangaishi, A., Miyawaki, S., Hirosawa, S., Miura, Y., Takeyama, K., Kamada, N., Ohtake, S., Uike, N., Shimazaki, C., Toyama, K., Hirano, M., Mizoguchi, H., Kobayashi, Y., Shinpe, F., Saito, M., Emi, N., Yazaki, Y., Ueda, R. and Hirai, H. (1995). Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies, Blood, 86, 1548–56.
   PubMed Web of Science ®Google Scholar
• Sill, H., Aguiar, C. T., Schmidt, H., Hochhaus, A., Goldman, J. M. and Cross, N. C. (1996). Mutational analysis of the p15 and p16 genes in acute leukaemias, Br J Haematol, 92, 681–3.
   PubMed Web of Science ®Google Scholar
• Tsubari, M., Tiihonen, E. and Laiho, M. (1997). Cloning and characterization of p10, an alternatively spliced form of p15 cyclin-dependent kinase inhibitor, Cancer Res, 57, 2966–2973.
   PubMed Web of Science ®Google Scholar
• Sakai, A., Thieblemont, C., Wellmann, A., Jaffe, E. S. and Raffeld, M. (1998). PTEN gene alterations in lymphoid neoplasms, Blood, 92, 3410–5.
   PubMed Web of Science ®Google Scholar
• Nakahara, Y., Nagai, H., Kinoshita, T., Uchida, T., Hatano, S., Murate, T. and Saito, H. (1998). Mutational analysis of the PTEN/MMAC1 gene in non-Hodgkin's lymphoma, Leukemia, 12, 1277–80.
   PubMed Web of Science ®Google Scholar
• Wang, Z. J., Taylor, F., Churchman, M., Norbury, G. and Tomlinson, I. (1998). Genetic pathways of colorectal carcinogenesis rarely involve the PTEN and LKB1 genes outside the inherited hamartoma syndromes, Am J Pathol, 153, 363–6.
   PubMed Web of Science ®Google Scholar
• Bergmann, L., Miething, C., Maurer, U., Brieger, J., Karakas, T., Weidmann, E. and Hoelzer, D. (1997). High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome, Blood, 90, 1217–25.
   PubMed Web of Science ®Google Scholar
• Banker, D. E., Groudine, M., Willman, C. L., Norwood, T. and Appelbaum, F. R. (1998). Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents, Leukemia Res, 22, 221–39.
   PubMed Web of Science ®Google Scholar